1
|
Rohmer J, Couteau‐Chardon A, Trichereau J, Panel K, Gesquiere C, Ben Abdelali R, Bidet A, Bladé J, Cayuela J, Cony‐Makhoul P, Cottin V, Delabesse E, Ebbo M, Fain O, Flandrin P, Galicier L, Godon C, Grardel N, Guffroy A, Hamidou M, Hunault M, Lengline E, Lhomme F, Lhermitte L, Machelart I, Mauvieux L, Mohr C, Mozicconacci M, Naguib D, Nicolini FE, Rey J, Rousselot P, Tavitian S, Terriou L, Lefèvre G, Preudhomme C, Kahn J, Groh M, Ackermann F, Adiko D, Ahwij N, Baruchel A, Beal C, Bemba M, Beylot Barry M, Beyne Rauzy O, Bielefeld P, Boisseau M, Bonmati C, Bonnote B, Borel C, Bouredji D, Brignier A, Brouillard M, Campos F, Carre M, Chalayer E, Chomel JC, Coiteux V, Contejean A, Corby A, Darre S, Dubruille V, Durel CA, El Yamani A, Etancelin P, Etienne N, Evon P, Gyan E, Hachulla E, Hermet M, Huguet F, Ianotto JC, Inchiappa L, Jdid I, Jondeau K, Joubert M, Legrand F, Lejeune C, Le Pendu C, Lidove O, Lemal R, Limal N, Lopinet E, Maloisel F, Marfaing A, Marroun I, Maurier F, Muller E, Muron T, Ojeda M, Paule R, Pignon JM, Rossi C, Roumier M, Sene D, Sene T, Simon L, Slama B, Suarez F, Tcherakian C, Torregrosa JM, Toussaint E, Vatan R, Visanica S, Voilat L, Zini JM. Epidemiology, clinical picture and long-term outcomes of FIP1L1-PDGFRA-positive myeloid neoplasm with eosinophilia: Data from 151 patients. Am J Hematol 2020; 95:1314-1323. [PMID: 32720700 DOI: 10.1002/ajh.25945] [Citation(s) in RCA: 34] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2020] [Accepted: 07/23/2020] [Indexed: 12/11/2022]
Abstract
FIP1L1-PDGFRA-positive myeloid neoplasm with eosinophilia (F/P+ MN-eo) is a rare disease: robust epidemiological data are lacking and reported issues are scarce, of low sample-size and limited follow-up. Imatinib mesylate (IM) is highly efficient but no predictive factor of relapse after discontinuation has yet been identified. One hundred and fifty-one patients with F/P+ MN-eo (143 males; mean age at diagnosis 49 years; mean annual incidence: 0.18 case per million population) were included in this retrospective nationwide study involving all French laboratories who perform the search of F/P fusion gene (study period: 2003-2019). The main organs involved included the spleen (44%), skin (32%), lungs (30%), heart (19%) and central nervous system (9%). Serum vitamin B12 and tryptase levels were elevated in 74/79 (94%) and 45/57 (79%) patients, respectively, and none of the 31 patients initially treated with corticosteroids achieved complete hematologic remission. All 148 (98%) IM-treated patients achieved complete hematologic and molecular (when tested, n = 84) responses. Forty-six patients eventually discontinued IM, among whom 20 (57%) relapsed. In multivariate analysis, time to IM initiation (continuous HR: 1,01 [0.99-1,03]; P = .05) and duration of IM treatment (continuous HR: 0,97 [0,95-0,99]; P = .004) were independent factors of relapse after discontinuation of IM. After a mean follow-up of 80 (56) months, the 1, 5- and 10-year overall survival rates in IM-treated patients were 99%, 95% and 84% respectively. In F/P+ MN-eo, prompt initiation of IM and longer treatment durations may prevent relapses after discontinuation of IM.
Collapse
Affiliation(s)
- Julien Rohmer
- National Reference Center for Hypereosinophilic syndromes (CEREO) Suresnes France
- Department of Internal Medicine Hôpital Foch Suresnes France
| | - Amélie Couteau‐Chardon
- National Reference Center for Hypereosinophilic syndromes (CEREO) Suresnes France
- Department of Intensive Care medicine Centre Hospitalier Annecy Genevois Saint‐Julien‐en‐Genevois France
| | - Julie Trichereau
- National Reference Center for Hypereosinophilic syndromes (CEREO) Suresnes France
- Clinical Research Department Hôpital Foch Suresnes France
| | - Kewin Panel
- National Reference Center for Hypereosinophilic syndromes (CEREO) Suresnes France
- Clinical Research Department Hôpital Foch Suresnes France
| | - Cyrielle Gesquiere
- National Reference Center for Hypereosinophilic syndromes (CEREO) Suresnes France
| | - Raouf Ben Abdelali
- Pole Hématologie et Oncologie Laboratoire CERBA Saint‐Ouen‐l'Aumône France
| | - Audrey Bidet
- Laboratory of Hematology CHU de Bordeaux Pessac France
| | | | - Jean‐Michel Cayuela
- Laboratory of Hematology Saint‐Louis Hospital, University of Paris Paris France
| | - Pascale Cony‐Makhoul
- National Reference Center for Hypereosinophilic syndromes (CEREO) Suresnes France
- Hematology Department CH Annecy Genevois Annecy France
| | - Vincent Cottin
- National Coordinating Reference Center for Rare Pulmonary Diseases Louis Pradel Hospital Lyon France
- Hospices Civils de Lyon, UMR754, University Claude Bernard Lyon 1 Lyon France
| | - Eric Delabesse
- Laboratory of Hematology Institut Universitaire du Cancer de Toulouse Oncopole, CHU de Toulouse Toulouse France
| | - Mikaël Ebbo
- National Reference Center for Hypereosinophilic syndromes (CEREO) Suresnes France
- Aix Marseille University, Department of Internal Medicine Hôpital de la Timone, AP‐HM, CNRS, INSERM, CIML Marseille France
| | - Olivier Fain
- Department of Internal Medicine CHU Saint Antoine Paris France
| | - Pascale Flandrin
- Laboratory of Hematology Hôpital Nord, CHU de Saint‐Étienne Saint‐Étienne France
| | - Lionel Galicier
- Department of Clinical Immunology Saint Louis hospital Paris France
| | - Catherine Godon
- Laboratoire de cytogénétique hématologique CHU de Nantes Nantes France
| | | | - Aurélien Guffroy
- National Reference Center for Hypereosinophilic syndromes (CEREO) Suresnes France
- Department of Clinical Immunology and Internal Medicine, National Reference Center for Systemic Autoimmune Diseases (RESO), Tertiary Center for Primary Immunodeficiency Strasbourg University Hospital Strasbourg France
| | - Mohamed Hamidou
- National Reference Center for Hypereosinophilic syndromes (CEREO) Suresnes France
- Department of Internal Medicine CHU de Nantes Nantes France
| | | | | | | | - Ludovic Lhermitte
- University of Paris, Institut National de Recherche Médicale U1151 Laboratory of Onco‐Hematology, Hôpital Necker Enfants‐Malades Paris France
| | - Irène Machelart
- National Reference Center for Hypereosinophilic syndromes (CEREO) Suresnes France
- Department of Internal Medicine CHU de Bordeaux Bordeaux France
| | - Laurent Mauvieux
- Université de Strasbourg, INSERM U1113 Interface de Recherche Fondamentale et Appliquée en Cancérologie, Laboratoire d'hématologie du CHRU Strasbourg, Faculté de Médecine de Strasbourg Strasbourg France
| | - Catherine Mohr
- Service d'Hématologie Oncologie, CHU Groupe Hospitalier Sud Réunion Saint Pierre, Reunion France
| | - Marie‐Joelle Mozicconacci
- Institut Paoli‐Calmettes, Centre de Recherche en Cancérologie de Marseille, Biopathologie Marseille France
| | - Dina Naguib
- Laboratory of Hematology CHU Caen Caen France
| | - Franck E. Nicolini
- Department of Hematology INSERM U 1052, CRCL, Centre Léon Bérard Lyon France
| | - Jerome Rey
- Department of Hematology Institut Paoli‐Calmettes Marseille France
| | - Philippe Rousselot
- Hematology Department Versailles André Mignot Hospital, University Paris‐Saclay Le Chesnay France
| | - Suzanne Tavitian
- Service d'Hématologie, Institut Universitaire du Cancer de Toulouse‐Oncopole Centre Hospitalier Universitaire de Toulouse Toulouse France
| | - Louis Terriou
- National Reference Center for Hypereosinophilic syndromes (CEREO) Suresnes France
- Université de Lille, CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto‐immunes Systémiques Rares du Nord et Nord‐Ouest de France (CeRAINO) Lille France
| | - Guillaume Lefèvre
- National Reference Center for Hypereosinophilic syndromes (CEREO) Suresnes France
- Université de Lille, CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto‐immunes Systémiques Rares du Nord et Nord‐Ouest de France (CeRAINO) Lille France
| | | | - Jean‐Emmanuel Kahn
- National Reference Center for Hypereosinophilic syndromes (CEREO) Suresnes France
- Université Paris‐Saclay, Department of Internal Medicine Ambroise Paré hospital, Boulogne Billancourt Cedex France
| | - Matthieu Groh
- National Reference Center for Hypereosinophilic syndromes (CEREO) Suresnes France
- Department of Internal Medicine Hôpital Foch Suresnes France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Fournier E, Inchiappa L, Delattre C, Pignon JM, Danicourt F, Bemba M, Roche-Lestienne C, Daudignon A, Decool G, Roumier C, Dumezy F, Fournier L, Grardel N, Preudhomme C, Duployez N. Increased risk of adverse acute myeloid leukemia after anti-CD19-targeted immunotherapies in KMT2A-rearranged acute lymphoblastic leukemia: a case report and review of the literature. Leuk Lymphoma 2019; 60:1827-1830. [DOI: 10.1080/10428194.2018.1562185] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Affiliation(s)
- Elise Fournier
- Laboratory of Hematology, CH Dunkerque, Dunkerque, France
- Laboratory of Hematology, CHU Lille, Lille, France
| | | | | | | | | | - Maxime Bemba
- Hematology Department, CH Dunkerque, Dunkerque, France
| | - Catherine Roche-Lestienne
- Department of Medical Genetics, CHU Lille, Lille, France
- INSERM UMR-S 1172, University of Lille, Lille, France
| | | | - Gauthier Decool
- Laboratory of Hematology, CHU Lille, Lille, France
- INSERM UMR-S 1172, University of Lille, Lille, France
| | - Christophe Roumier
- Laboratory of Hematology, CHU Lille, Lille, France
- INSERM UMR-S 1172, University of Lille, Lille, France
| | - Florent Dumezy
- Laboratory of Hematology, CHU Lille, Lille, France
- INSERM UMR-S 1172, University of Lille, Lille, France
| | - Loïc Fournier
- Laboratory of Hematology, CH Dunkerque, Dunkerque, France
| | - Nathalie Grardel
- Laboratory of Hematology, CHU Lille, Lille, France
- INSERM UMR-S 1172, University of Lille, Lille, France
| | - Claude Preudhomme
- Laboratory of Hematology, CHU Lille, Lille, France
- INSERM UMR-S 1172, University of Lille, Lille, France
| | - Nicolas Duployez
- Laboratory of Hematology, CHU Lille, Lille, France
- INSERM UMR-S 1172, University of Lille, Lille, France
| |
Collapse
|
3
|
Renaud L, Nibourel O, Marceau-Renaut A, Gruson B, Cambier N, Lionne-Huyghe P, Choufi B, Rodriguez C, Frimat C, Plantier I, Stalnikiewicz L, Bemba M, Berthon C, Marolleau JP, Quesnel B, Preudhomme C, Duployez N. Comprehensive molecular landscape in patients older than 80 years old diagnosed with acute myeloid leukemia: A study of the French Hauts-de-France AML observatory. Am J Hematol 2019; 94:E24-E27. [PMID: 30358899 DOI: 10.1002/ajh.25328] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2018] [Revised: 10/17/2018] [Accepted: 10/20/2018] [Indexed: 11/05/2022]
Affiliation(s)
- Loïc Renaud
- Department of Hematology; CHU Lille; Lille France
- Inserm, UMR-S 1172; Lille France
| | - Olivier Nibourel
- Inserm, UMR-S 1172; Lille France
- Laboratory of Hematology; CHU Lille; Lille France
| | - Alice Marceau-Renaut
- Inserm, UMR-S 1172; Lille France
- Laboratory of Hematology; CHU Lille; Lille France
| | | | - Nathalie Cambier
- Department of Hematology; Hôpital St Vincent; Lille France
- Department of Hematology; CH Valenciennes; Valenciennes France
| | | | - Bachra Choufi
- Department of Hematology; CH Boulogne-sur-mer; Boulogne-sur-mer France
| | | | | | | | | | - Maxime Bemba
- Department of Hematology; CH Dunkerque; Dunkerque France
| | - Céline Berthon
- Department of Hematology; CHU Lille; Lille France
- Inserm, UMR-S 1172; Lille France
| | | | - Bruno Quesnel
- Department of Hematology; CHU Lille; Lille France
- Inserm, UMR-S 1172; Lille France
| | - Claude Preudhomme
- Inserm, UMR-S 1172; Lille France
- Laboratory of Hematology; CHU Lille; Lille France
| | - Nicolas Duployez
- Inserm, UMR-S 1172; Lille France
- Laboratory of Hematology; CHU Lille; Lille France
| |
Collapse
|
4
|
Duployez N, Chebrek L, Helevaut N, Fournier E, Bemba M, Caillault A, Geffroy S, Preudhomme C. A novel type of NPM1 mutation characterized by multiple internal tandem repeats in a case of cytogenetically normal acute myeloid leukemia. Haematologica 2018; 103:e575-e577. [PMID: 29903763 DOI: 10.3324/haematol.2018.190959] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Affiliation(s)
- Nicolas Duployez
- CHU Lille, Laboratory of Hematology .,Univ. Lille, INSERM, UMR-S 1172
| | | | - Nathalie Helevaut
- CHU Lille, Laboratory of Hematology.,Univ. Lille, INSERM, UMR-S 1172
| | - Elise Fournier
- Univ. Lille, INSERM, UMR-S 1172.,CH Dunkerque, Laboratory of Hematology, F-59385
| | - Maxime Bemba
- CH Dunkerque, Hematology Department, F-59385, France
| | | | - Sandrine Geffroy
- CHU Lille, Laboratory of Hematology.,Univ. Lille, INSERM, UMR-S 1172
| | - Claude Preudhomme
- CHU Lille, Laboratory of Hematology.,Univ. Lille, INSERM, UMR-S 1172
| |
Collapse
|
5
|
Desoutter J, Gay J, Berthon C, Ades L, Gruson B, Geffroy S, Plantier I, Marceau A, Helevaut N, Fernandes J, Bemba M, Stalnikiewicz L, Frimat C, Labreuche J, Nibourel O, Roumier C, Figeac M, Fenaux P, Quesnel B, Renneville A, Duhamel A, Preudhomme C. Molecular prognostic factors in acute myeloid leukemia receiving first-line therapy with azacitidine. Leukemia 2015; 30:1416-8. [PMID: 26582646 DOI: 10.1038/leu.2015.314] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Affiliation(s)
- J Desoutter
- Laboratoire d'hématologie, Centre de Biologie Pathologie, CHRU Lille, Université Lille 2, Lille, France
| | - J Gay
- Service d'hématologie clinique, Hôpital Saint Antoine, Université Paris 6, APHP, Paris, France
| | - C Berthon
- Service d'hématologie clinique, CHRU Lille, Université Lille 2, Lille, France
| | - L Ades
- Service d'hématologie clinique, Hôpital d'Avicenne, Université Paris 13, Bobigny, France
| | - B Gruson
- Service d'hématologie clinique, CHU Amiens-Picardie, Amiens, France
| | - S Geffroy
- Laboratoire d'hématologie, Centre de Biologie Pathologie, CHRU Lille, Université Lille 2, Lille, France
| | - I Plantier
- Service d'hématologie clinique, Hôpital de Roubaix, Roubaix, France
| | - A Marceau
- Laboratoire d'hématologie, Centre de Biologie Pathologie, CHRU Lille, Université Lille 2, Lille, France
| | - N Helevaut
- Laboratoire d'hématologie, Centre de Biologie Pathologie, CHRU Lille, Université Lille 2, Lille, France
| | - J Fernandes
- Service d'hématologie clinique, Hôpital de Valenciennes, Valenciennes, France
| | - M Bemba
- Service d'hématologie clinique, Hôpital de Dunkerque, Dunkerque, France
| | - L Stalnikiewicz
- Service d'hématologie clinique, Hôpital de Lens, Lens, France
| | - C Frimat
- Laboratoire d'hématologie, Centre de Biologie Pathologie, CHRU Lille, Université Lille 2, Lille, France
| | - J Labreuche
- Unités de Biostatistiques, CHRU Lille, Université Lille 2, Lille, France
| | - O Nibourel
- Laboratoire d'hématologie, Centre de Biologie Pathologie, CHRU Lille, Université Lille 2, Lille, France
| | - C Roumier
- Laboratoire d'hématologie, Centre de Biologie Pathologie, CHRU Lille, Université Lille 2, Lille, France
| | - M Figeac
- Plateforme de génomique structurale et fonctionnelle, IFR-114, Université Lille 2, Lille, France
| | - P Fenaux
- Service d'hématologie clinique, Hôpital Saint-Louis, Université Paris 7, APHP, Paris, France
| | - B Quesnel
- Service d'hématologie clinique, CHRU Lille, Université Lille 2, Lille, France
| | - A Renneville
- Laboratoire d'hématologie, Centre de Biologie Pathologie, CHRU Lille, Université Lille 2, Lille, France
| | - A Duhamel
- Unités de Biostatistiques, CHRU Lille, Université Lille 2, Lille, France
| | - C Preudhomme
- Laboratoire d'hématologie, Centre de Biologie Pathologie, CHRU Lille, Université Lille 2, Lille, France
| |
Collapse
|
6
|
Lannoy D, Decaudin B, Barrier F, Bemba M, Wierre L, Pignon JM, Horrent S, Résibois JP, Wetterwald M, Odou P. Ostéonécrose avasculaire de la machoire sous diphosphonates. Therapie 2006; 61:363-5. [PMID: 17124954 DOI: 10.2515/therapie:2006061] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
7
|
Bemba M, Guardiola P, Garderet L, Devergie A, Ribaud P, Esperou H, Noguera MH, Gluckman E, Socie G. Bone marrow transplantation for paroxysmal nocturnal haemoglobinuria. Br J Haematol 1999. [DOI: 10.1111/j.1365-2141.1999.01374.x] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
8
|
Bemba M, Guardiola P, Garderet L, Devergie A, Ribaud P, Esperou H, Noguera MH, Gluckman E, Socié G. Bone marrow transplantation for paroxysmal nocturnal haemoglobinuria. Br J Haematol 1999; 105:366-8. [PMID: 10233405] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
Abstract
Paroxysmal nocturnal haemoglobinuria (PNH) is an acquired clonal disorder of the haemopoietic stem cells for which the only curative treatment is bone marrow transplantation. There are few reports on the use of allogeneic transplantation for PNH, and nearly all of them include only a few patients. Between September 1978 and December 1997, 16 patients underwent marrow transplantation for PNH at the Hospital Saint Louis. The 5-year survival rate for the 16 patients was 58 +/- 13%. Two factors, an absolute neutrophil count >1.0 x 109/l and haemoglobin level >9 g/dl at transplant, were found to be statistically associated with a better outcome.
Collapse
Affiliation(s)
- M Bemba
- Service d'Hématologie-Greffe de Moelle, Hôpital Saint-Louis, Paris Cedex, France
| | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Albin N, Bemba M, Gabarre J, Sutton L, Leblond V. [Intensive therapy in non-Hodgkins lymphoma. Indications and modalities]. Presse Med 1998; 27:977-85. [PMID: 9767846] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/09/2023] Open
Affiliation(s)
- N Albin
- Département d'Hématologie, Groupe Hospitalier Pitié-Salpêtrière, Paris
| | | | | | | | | |
Collapse
|